hentrep

Tragically fascinating real-time footage of the Bridge Fire in Southern California. Interesting to see the fire advance over the course of 14 hours.

More here: https://www.vvdailypress.com/story/news/fire/2024/09/10/line...

As a reMarkable 2 owner, I’ve tried so hard to integrate the device into my day to day. Unfortunately, the software is an absolute disaster. Sync is chronically broken. The lag between switching notebooks or sometimes just turning pages is annoying. Every software update seems to introduce new new bugs at a rate higher than those being fixed. Don’t just take my word for it. Go check out the reMarkable subreddit - nearly everyone issues this tablet.

I’ve since reverted back to old-fashioned pen and paper. There’s a certain magic about the visual-muscle memory. It generally takes me just a few seconds to find a many months old note in a full notepad.

For anyone considering this advice, please do your research on reMarkable’s software issues. The usual tech adage holds true: it is rare to find hardware companies who can do software right.

Interestingly, there seems to be a pattern at the University of Maryland. Or perhaps they're just more vigilant in the policing.

1. "Former U Maryland researcher faked data in seven papers, two Federal grants" https://retractionwatch.com/2020/05/13/former-u-maryland-res...

2. "Former Maryland researcher banned from Federal funding for misconduct" https://retractionwatch.com/2020/08/14/former-maryland-resea...

Covered in 2014: https://www.businessinsider.com/how-noah-kagan-got-fired-fro...

Start9 offers this. No experience with their servers, but looks interesting: https://start9.com/

There are several approved: Xofigo, Pluvicto, Lutathera

Disclaimer: Haven’t read the article.

Radiation has benefits that your chemical cytotoxics do not. An individual tumor often comprises of many subclonal cancer cell populations, all of which could have unique resistance mechanisms to allow that subclone to survive and proliferate in the presence of a single cytotoxic payload (say from an antibody-drug conjugate).

Targeting cancer cells with a radioactive payload can bypass many resistance mechanisms common to cytotoxic payloads.

Pluvicto (lutetium-177) is one of the hotter radioligand therapies as of late (approved for metastatic prostate cancer). Take a look at Fig 1a here - the responses can be quite striking for patients with extensive metastatic disease: https://www.frontiersin.org/articles/10.3389/fnume.2023.1291...

What I find most interesting are the supply chain challenges and logistics for radioligand therapies. Given the half-life of the payload, this is not something one can just manufacture and set on a shelf for the next patient. And of course the regulations involved with anything radioactive provide additional challenges.

Your last sentence is subjective. I grew up eating bear sausage and it was delicious. Perhaps owing to differences in black bear diet/meat vs Alaskan bear. This article seems to corroborate my suspicions: https://www.outdoorlife.com/hunting/bear-meat/

Gritstone Bio is working in this space and have in-house manufacturing capabilities. Still a ways from prime time, but fascinating technology and an innovative approach. [0]

[0] https://gritstonebio.com/

For anyone searching in the future, I wanted to share this post about physically disconnecting the air card in a JL Wrangler: https://www.jlwranglerforums.com/forum/threads/anyone-enjoy-...

Thank you!

I’d love to read more - can you share a link?

No, I wouldn’t. And I appreciate the Boston Dynamics track record. That said, they do have a reputation for viral video releases. Curiously, they usually show some sort of human interaction with their new robots, but maybe too early here? Particularly loved the video of the engineer shoving the robot as it negotiated an obstacle course.

Would you bet money that it isn’t CGI? The fact that we are asking these questions is just as terrifying and impressive as the malicious potential of the robot itself. Wild days we’re living in!

Maybe it’s just the lighting, but this look like CGI to me.

This is actually one of the goals in colorectal cancer - organ-sparing treatment options. In particular, using immunotherapies in the neoadjuvant, peri-operative setting has shown tremendous benefit in colorectal cancers. Work done by Myriam Chalabi (Netherlands Cancer Institute) with the NICHE-1 study [0] and Pashtoon Kasi (Cornell) with the NEST-1 study [1] have had tremendous impacts for the up to 15% of patients who have mismatch repair deficient CRC.

[0] https://ascopost.com/issues/october-25-2022/unprecedented-wa... [1] https://www.nyp.org/advances/article/gastroenterology/ongoin...

For reference, dostarlimab (JEMPERLI) is essentially GSK's answer to Merck's pembrolizumab and BMS's nivolumab. Or KEYTRUDA and OPDIVO, respectively, if you're in the USA and bombarded with pharma ads. All three are monoclonal antibodies that block PD-1 on T cells, thereby stimulating the body's immune system.

At risk of taking the bait with this flippant comment, I’d like to highlight your critique of what others used to long for as “targeted therapy” or “personalized medicine”. I suppose we could always step backward to a world dominated by systemic cytotoxic chemo, though. Which, to be fair, still has its place.

Cancer tends to evolve at a rate that outpaces treatment innovation, and the molecular determinants can be wildly heterogenous. For example, a lung cancer patient can have half a dozen tumors that all harbor independent oncogenic drivers. It is not uncommon for a patient to undergo treatment with a target therapy and see complete tumor responses in some lesions, while others grow unimpeded.

We did not develop our own code base. Humans are a black box and drug development is HARD.

This Yahoo news article is from February 2023, and the original in Science is from 2021 [0]. Just in case anyone thunks this is breaking research.

[0] https://www.science.org/doi/10.1126/science.abe5017

> potentially affecting 15,363 individuals in the United States, including 76 in the state of Maine.

Odd that Roku singles out the 0.5% of users affected within the state of Maine. Must be related to some sort of Maine data breach law? I didn't dig too deeply, but not seeing anything explicitly called out in their statutes [0].

[0] https://legislature.maine.gov/legis/statutes/10/title10sec13...

Kaiser Permanente has something similar for their med school in Pasadena. In 2019 they announced free med school tuition for the first 5 classes (through 2024). Unsurprisingly this attracts top talent, and there don’t appear to be any sort of strings attached (eg, stay employed with Kaiser for X years once you finish).

Their acceptance rate was 50/11,000 applicants last year (0.45%).

[0] https://www.nbclosangeles.com/news/health-wellness/kaiser-pe...

I booked a flight on United yesterday, well after this latest Boeing incident. After looking more carefully, they have me on a 737 MAX 9. I haven’t kept up with the latest, but I thought all of these planes were grounded. Am I missing something, or am I just setting myself up for a canceled flight next week?

Was about to note the same. Low single-digit shifts in the stock of a multi-trillion dollar company can be misleading!

Discussed here a few days ago: https://news.ycombinator.com/item?id=38054531

Reminds me of the hours I used to spend zooming around Google Maps when they had the Wikipedia overlay. I desperately miss that feature!

They detail this in the supplementary materials: https://static-content.springer.com/esm/art%3A10.1038%2Fs415...

>Stock is still the easiest, safest, cheapest option - VS your own shoot.

Can you elaborate on what you mean by "safest" vs shooting your own?

I’m writing this live from the ASCO meeting where this was just presented. Osimertinib (TAGRISSO) has truly transformed the way we treat EGFR-mutant NSCLC, having repeatedly redefined standards of care. I don’t have a source handy, but osi used to hold a record in oncology as being the fastest drug to go from IND (trial-enabling) to approval - less than 18 months.

Osimertinib did $5.44B in global sales last year, leading AstraZeneca’s oncology portfolio [0]

[0] https://www.astrazeneca.com/content/dam/az/PDF/2022/fy/Full-...

Related episode of Radiolab from 2014: https://radiolab.org/podcast/9-volt-nirvana

Full text link for anyone curious: https://www.lightspeedmagazine.com/fiction/exhalation/

Also related, the ghost town of Singapore, MI: https://en.wikipedia.org/wiki/Singapore,_Michigan

The shores of West Michigan are truly a gem!